

# Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

## Spark YG(TM) 593 anti-human CD19

RRID:AB\_2894448

Type: Antibody

---

### Proper Citation

BioLegend Cat# 302279, RRID:AB\_2894448

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2894448](http://antibodyregistry.org/AB_2894448)

**Proper Citation:** BioLegend Cat# 302279, RRID:AB\_2894448

**Target Antigen:** CD19

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Spark YG(TM) 593 anti-human CD19

**Description:** This monoclonal targets CD19

**Target Organism:** human

**Clone ID:** clone HIB19

**Antibody ID:** AB\_2894448

**Vendor:** BioLegend

**Catalog Number:** 302279

**Alternative Catalog Numbers:** 302280

**Record Creation Time:** 20250820T005332+0000

**Record Last Update:** 20250820T092846+0000

---

### Ratings and Alerts

No rating or validation information has been found for Spark YG(TM) 593 anti-human CD19.

No alerts have been found for Spark YG(TM) 593 anti-human CD19.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Benmebarek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity, 58(4), 926.

Mavuluri J, et al. (2025) GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR T-cell Resistance via Macrophage Remodeling. Cancer discovery, 15(5), 1018.